To review the recent literature on the relation between depression and coronary heart disease (CHD), including both etiologic studies (that is, depression preceding development of CHD) and prognostic studies (that is, depression predicting prognosis in established CHD), and to assess the degree to which the literature supports a causal interpretation of the link between depression and CHD.
T he relation between depression and CHD has been a subject of research for more than 30 years, and over that time, the evidence of links between them has continued to grow. It is well established that hospitalized patients with CHD, including post-MI patients, patients with congestive heart failure, those recovering from attacks of unstable angina, and patients undergoing coronary bypass surgery or angioplasty, show higher prevalences of elevated depressive symptoms (30% to 50%) and higher rates of major depression (15% to 20%) than do people of similar age and sex living in the general community (1) . Although increased levels of depression are common in many chronic and acute illnesses (2) , the rates in CHD patients may be particularly important. An increasing body of literature shows that depression is associated with a worse prognosis in patients with established CHD and that depression may even increase the risks of developing CHD in initially healthy individuals. Today, many believe that depression is a risk factor for CHD of the same importance as other more standard risks, including diabetes, lack of exercise, and smoking. Nevertheless, depression is not recognized as a cardiac risk factor by North American cardiology and heart associations, and its status remains controversial among many psychiatrists and cardiologists. However, an editorial in 2005 in the prestigious cardiology journal Circulation (3) called for recognition of the importance of depression in cardiovascular disease. Attitudes may be changing. Undoubtedly, one of the reasons for this apparent shift has to do with the sheer amount of research that has accumulated on the relation between depression and CHD. Nonetheless, because this research is almost exclusively correlational in nature, the controversy over whether or not depression is a cardiac risk factor is likely to continue.
Risk factors are variables associated with an increased chance of developing or showing a worsening of a health problem.
The identification of risk factors is useful from a public health perspective because it helps to target prevention efforts. Because people cannot be randomly assigned either to have or not have risk factors, establishing that a particular variable (such as a high cholesterol level or depression) is a risk factor involves making causal inferences from correlational data. To build this causal case, epidemiologists often evaluate the available scientific literature, using rule-of-thumb criteria drawn from the writings of Sir Austin Bradford Hill (4) and the work of the US Surgeon General's Advisory Committee on Smoking and Health (5) . These criteria include the following:
1. The presence of an objective outcome measure, in this case, an objective measure of CHD, not self-reported hospital admission or heart disease.
2. Use of prospective, not cross-sectional, designs.
3. Evidence of a consistent, strong, and dose-response association between the risk factor and the outcome.
4.
Evidence that the association between the risk factor and the outcome is not explained by other variables or covariates linked to both.
5.
Existence of biologically plausible mechanisms to account for the observed links.
6. Evidence from clinical trials that changing the risk results in changing the outcome.
In a previous article (6), we reviewed the literature concerning the research about depression as a coronary risk factor that was published before December 15, 2003 . This review updated an earlier comprehensive review of the literature published by Kuper, Marmot, and Hemingway (7) . Both reviews considered the evidence for the link between depression and the development of CHD in initially disease-free individuals (that is, depression as an etiological risk), as well as the relation between depression and prognosis in patients with CHD (that is, depression as a prognostic risk). We concluded:
Despite multiple methodological differences from study to study, the data from prospective adequately powered etiologic and prognostic studies with objective outcome measures and recognized indices of depression are remarkably consistent in their support of depression as a risk factor for both the development and the worsening of CHD (6, p S23).
We also predicted that, with increased use of standardized approaches to assess depression and cardiac outcomes, the evidence would likely grow stronger. There have been many publications in the 2 years since we drew that conclusion. This article updates our previous review to provide a summary of knowledge about depression and CHD through December 15, 2005, paying special attention to the extent to which the evidence supports making causal inferences.
Methods
We searched the MEDLINE, Current Contents, and PsycINFO computerized databases for combinations of the following terms:
1. Coronary heart disease (CHD), coronary artery disease, ischemic heart disease, myocardial infarction (MI), unstable angina, acute coronary syndrome, coronary bypass surgery, atherosclerosis, sudden death, and ventricular fibrillation or ventricular tachycardia.
2. Mortality and survival or prognosis.
3. Depression, depressive symptoms, and dysthymia or mood.
We also added the term "depressive disorder," as suggested by a reviewer of our previous paper. We limited the dates of publication to the window between December 15, 2003, and December 15, 2005 . As previously discussed, we only considered studies with prospective designs (not case-control designs or cross-sectional data); etiologic studies with sample sizes of at least 500; prognostic studies with samples sizes of at least 100; reports that used recognized indices of major depression or depressive symptoms or measures with recognized depression subscales; those that reported fatal CHD, sudden cardiac death, incident nonfatal MI, incident angina, incident heart failure; and for prognostic studies only, those that reported all-cause mortality, as long as they reported at least one outcome other than angina or self-reported chest pain. We did not include studies that identified depression from antidepressant treatment, self-reported depression treatment, single-item measures, or study-specific measures or that mislabelled nonspecific screening indices of probable psychiatric caseness as measures of depression.
Results
Applying the above criteria, we found 8 recent publications that included etiologic data (8) (9) (10) (11) (12) (13) (14) (15) ) and 16 publications with prognostic data (14-30) (3 of which were additional publications from previously published studies [19, 25, 29] ). In addition, 2 of the recent publications presented both etiologic and prognostic data (14, 15) . We also found 23 new review papers, including 4 that appeared in a special supplement of Psychosomatic Medicine (31) devoted to the links between depression and heart disease. Altogether, between 1964 and 2005, there were 29 publications of etiologic data and 59 publications of prognostic data (including 3 papers that presented both etiologic and prognostic subgroups) that met our inclusion criteria. Because there were multiple publications from the same databases, these publications represent only 65 original studies (21 etiologic, 41 prognostic, and 3 presenting both types of data). Over this same period, we located 102 review papers that summarized at least a portion of the existing data without presenting any additional primary data.
This sizeable body of primary data and informative commentary is extremely difficult to summarize, given the heterogeneity of sample characteristics, measures of depression, timing of measures, length of follow-up periods, and definition of cardiac disease outcomes. In fact, given this diversity, it is not surprising that only 4 of the review papers identified by our literature search applied metaanalytic techniques (32) (33) (34) (35) . Although a total of 14 etiologic studies published before the end of 2000 were included in the metaanalyses by Wulsin and Singal (32) and Rugulies (33) , their selection criteria differed slightly, and the 2 papers shared a core group of only 7 studies. Nonetheless, they came to almost identical conclusions. Wulsin and Singal concluded that "The combined overall relative risk of depression leading to the onset of coronary disease was 1.64 (95%CI, 1.41 to 1.90)" (32, p 204). Rugulies found that "For all studies, the overall RR was 1.64 (95%CI, 1.29 to 2.08)" (33, p 56). Rugulies carried out additional analyses that suggested a stronger link between major depression and the development of CHD than between depressive symptoms and CHD. However, only 3 studies measured major depression.
The metaanalyses of prognostic studies by Van Melle and others (35) and Barth and others (34) were published together in the same issue of Psychosomatic Medicine. Both covered studies published through the end of 2003, and although there were small differences in inclusion criteria, as pointed out in the accompanying editorial by Carney and Sheps (36) , and although both reported a good deal of methodological variation in the studies reviewed, the results were strikingly similar. Von Melle and others looked at 22 studies of post-MI patients and concluded that "post-MI depression is associated with a 2-to 2.5-fold increased risk of impaired cardiovascular outcome" (35, p 814). Barth and others (34) included 20 long-term follow-up studies of individuals who had a CHD event, including MI, coronary bypass surgery, coronary angioplasty, or angiographically documented CHD. They concluded that "the risk of depressed patients dying in the two years after the initial assessment is two times higher than that of nondepressed patients" (34, p 802). They also noted some evidence that the link between depression and prognosis was stronger in earlier studies than in those published more recently. Both metaanalyses also reported some attenuation of the relation between depression and long-term cardiac depression after adjustment for covariates, but in both cases the impact remained statistically significant. In short, the bulk of the evidence published through 2003, either in individual studies or summarized in metaanalyses and critical reviews, suggests not only that there is an increased risk of developing CHD in individuals who experience depression but also that, in patients with established CHD, depression is associated with an increased risk of mortality and cardiac events above and beyond the impact of cardiac disease severity.
Summary of Etiologic Studies Published Between 2003 and 2005
The new etiologic studies published during the period between 2003 and 2005 provide data on close to an additional 112 000 individuals initially free of cardiac disease, including women in the WHI-OS (15) Among the 192 participants who were apparently free of cardiovascular disease at baseline, baseline depression was not significantly related to all-cause mortality or cardiovascular mortality after adjustment for sex, smoking, alcohol use, and number of comorbid conditions. Clearly, a group of individuals who have managed to achieve the age of 85 years without manifest cardiovascular disease are likely to be both genetically and behaviourally special in some way, compared with most individuals. In contrast to the lack of a significant relation between depression and outcome for this elderly sample without cardiovascular disease, among the 306 Leiden participants with cardiovascular disease at baseline, depression was significantly related to both all-cause and cardiovascular mortality, even after covariate adjustment. Wulsin and colleagues (8) examined data from 3634 individuals who were included in the original Framingham Heart Study or the Framingham offspring cohort and who were free of cardiac disease when the CES-D scale was administered. They were followed for 6 years for the occurrence of hard CHD outcomes (that is, cardiac death or nonfatal MI) and all-cause mortality. As CES-D scores increased, so did overall mortality rate, with the increase in risk remaining significant after adjustment for sex, age, hypertension, diabetes, body mass index, cholesterol, and alcohol use. The initial evidence of a similar relation for hard CHD incidence did not remain significant after covariate adjustment. The authors suggest several alternative interpretations for their lack of positive findings concerning CHD incidence, including a relatively short follow-up period and the fact that the average age in their sample was only 53 years, which resulted in a low number of incident cases of CHD and reducing study power.
Summary of Prognostic Studies Published between 2003 and 2005
The prognostic studies published between 2003 and 2005 extend the evidence of risk associated with depression to include patients undergoing valve surgery (30) , those with implantable defibrillators (16) , and those older than age 85 years with cardiovascular disease (14) . In addition, they add to the earlier prognostic evidence for congestive heart failure patients (20, 22) and for patients with recent acute coronary syndrome episodes (17, 21) . However, 6 of the recent prognostic studies reported nonsignificant covariate-adjusted associations between depression and cardiac and all-cause mortality outcomes (15, 18, 23, 24, 26, 27) . Five of these had sample sizes smaller than the 600-to 950-patient sample size estimated as necessary to assure adequate power to avoid false-negative results (6, 37) , and 4 had samples of fewer than 210 patients. Unfortunately, small etiologic studies showing a nonsignificant link between depression and cardiac outcomes continue to be published, mostly without mentioning low power as a potential explanation for results. These studies constitute noise that makes it difficult to have a clear picture of the field.
The only large, recent prognostic study that found no significant link between depression and cardiac outcomes after adjustment for covariates was the study with a subgroup of 18 572 postmenopausal women with previous cardiovascular disease who were followed for an average of 4.1 years as part of the WHI-OS (15) . In that group, however, there was a significant covariate-adjusted link between depression and stroke. Further, among the 73 098 women in the WHI-OS who did not have cardiovascular disease at the beginning of the study, depression was significantly related to cardiovascular mortality, all-cause mortality, and stroke, even after adjustment for traditional cardiac risk factors, age, ethnicity, education, and income.
Methodological Variability in Recent Studies
In our review of the literature through 2003, we noted that 23 different measures of depression had been used, even without considering the studies that used different cut points for the same scale or different combinations of measures. In the update through 2005, the number of ways in which depression was assessed climbed to 32. It can be hoped that the recently published report of the National Heart, Lung, and Blood Institute Working Group on the Assessment and Treatment of Depression in Patients with Cardiovascular Disease (38) will lead to greater consistency in measuring depression in future research. Briefly, that report recommends depression measures for use in epidemiologic studies, for screening and diagnosis of subjects to be enrolled in clinical trials, and for assessing depression severity over the course of clinical trials.
In epidemiologic studies of the type discussed in this review, the Working Group recommends the use of any of 3 self-report measures for depressive symptom severity: the BDI Version I (39), the BDI Version II (40) , and the Inventory for Depressive Symptoms (41) used in the STAR*D trial of algorithms for treatment-resistant depression (42) . For epidemiologic studies seeking to use diagnostic measures of depression, the recommendations include 1 of 2 highly structured interviewer-administered indices: the Depression Inventory and Structured Hamilton (43) , which was developed for use in the ENRICHD study (44) , or the Composite International Diagnostic Interview (45) . Although the report recognizes that the high depression prevalences obtained with the Composite International Diagnostic Interview in the National Comorbidity Survey (46) are suggestive of potential problems, no better widely used alternative is currently available.
In the literature prior to the end of 2003, we found an average of 2.8 cardiac outcomes (range 1 to 13) per study. The recent literature was similar, with an average of 2.3 outcomes (range 1 to 6). In the recent literature, we also noted fewer outcomes per study in the prognostic than in the etiologic research, probably reflecting the fact that most of the etiologic papers were based on large longitudinal cohort designs collected for multiple purposes. The recent papers also continued to show multiple operationalizations for cardiac outcome variables identified with the same name, although they showed more consistency than previously in their inclusion of all-cause mortality as an end point, a change that will facilitate future comparisons across studies.
Summary of Evidence in Relation to the First 4 Criteria for Causality
For both etiologic and prognostic studies, there is largely consistent evidence from prospective designs combining objective outcome measures, recognized depression assessments, and reasonable sample sizes that depression is associated with an increased chance of developing and worsening CHD and that this relation is not better explained by covariates. A dose-response relation means that there is a linear relation between increasing depression severity and increased risk of developing CHD or a worse prognosis in those with CHD. Our reading is that 16 of the total of 29 etiologic publications that appeared through the end of 2005 included an analysis of depression as a continuous variable or used multiple categories of increasing severity. Eleven of these support a gradient between depression severity and the development of CHD. Interestingly, prior to 2003, the majority of etiologic publications (13 of 21) included analyses that could be interpreted in terms of a dose-response relation. Since that time, such analyses have been less frequent, with only 3 of 8 recent studies reporting this type of data.
The question of whether or not there is a dose-response relation between depression severity or number of depression symptoms and prognosis in patients with established CHD has been less widely examined. Prior to 2003, only 3 of 43 publications examined the question of dose response, and only 5 of the 16 published since that time have included analyses of continuous or multicategory assessments of depression. However, when reported, the results are consistent, with 7 of the 8 assessments of a dose-response relation between depression severity and cardiac prognosis supporting a gradient of risk.
Although statistically oriented researchers have strongly argued against the common practice of dichotomizing continuous variables such as measures of depression symptoms (47) , recent literature has not tended to follow this advice. In fact, even though the continuity debate has continued for years in the general literature on depression (48) as well as in the literature on cardiac disease and depression (33) , depression research in cardiac patients has not contributed much to this debate.
Plausible Biological Mechanisms
Various plausible behavioural and biological mechanisms have been suggested to explain the links between depression and CHD. However, because the accompanying paper by Skala, Freedland, and Carney (49) provides an update of recent research in this area, we do not discuss mechanisms any further in this review.
Evidence That Treating Depression Changes Cardiac Outcome
Despite the existence for many years of a significant body of literature suggesting that depression is a risk factor both for the development of CHD and for its worsening in those with established disease, only one randomized efficacy study of antidepressant treatment in patients with CHD has been published, and only one trial has attempted to evaluate the impact on cardiac events of treating depression in CHD patients. To our knowledge, there have been no trials seeking to prevent the development of CHD through treating or preventing depression in individuals who have not had cardiac events.
SADHART (50) , the only placebo-controlled trial examining the safety and efficacy of an antidepresssant in CHD patients yet published, was a multisite trial that randomly assigned 369 post-MI patients with depression and with only mild-to-moderate ventricular dysfunction (Killip Class I and II) to 24 weeks of sertraline (50 to 200 mg) or placebo. The results showed sertraline to be safe from a cardiovascular point of view but found that it is not much more effective than placebo for treating depression in post-MI patients. The overall impact on the HDRS score (51) was not significant. Conversely, the impact for subgroups involving those with a recurrent depression and those with at least 2 previous depressions plus more severe baseline symptomatology was statistically significant. However, even for them, the effect size of the difference between sertraline and placebo was small-about one-half of the mean effect size reported for standard randomized controlled trials of Phase III antidepressant trials among patients without CHD but with major depression (52)-in part because of a higher placebo response. There was no evidence of efficacy for patients experiencing a first depression following an MI. Despite great hopes for success (53) , the recently published abstract of the first results from the Myocardial Infarction Depression Intervention Trial (54) does not provide any additional positive evidence of treatment efficacy. This trial evaluated the cardioprotective effect of an antidepressant strategy beginning with mirtazapine in 209 treatment patients who were compared with 122 patients who received usual care. Results over 18 months showed that this approach was neither cardioprotective nor efficacious in improving depression. However, sample size and methodological issues may be partly responsible.
Finally, although we hope to release new data within the next year on the efficacy of citalopram and interpersonal psychotherapy among stable CHD patients with major depression (55), the evidence base concerning the efficacy of treatments for depression in CHD patients will still remain small, whatever our results show.
The ENRICHD study (56) , funded by the US National Heart, Lung and Blood Institute, attempted to alter cardiac prognosis by treating depression. It involved 2481 post-MI patients identified during hospitalization as having major depression and (or) social isolation. The final sample included 647 patients who were socially isolated and without depression, with the remaining 1834 having major depression. ENRICHD was a multisite, randomized trial of 6 months of CBT supplemented by sertraline for patients who did not show improvement after 5 weeks. Patients randomly assigned to the control group received usual care from their physicians and physicians were informed of their patients' depression status. The results were disappointing. After an average of 29 months of follow-up, there was no evidence for an impact of treatment on the combined end point of death or nonfatal MI (P = 0.94). At 6 months, among the patients who suffered from depression at the time of randomization, there was a difference between the treatment and usual care groups of about 3 points in BDI scores (P < 0.001) and of about 2 points on the 17-item HDRS (P < 0.001). This effect size for CBT is similar to the effect size observed for sertraline in the SADHART. Additional analyses revealed that, by the end of the follow-up period, 20.6% of the depression patients in the usual care group had received antidepressant medication, compared with 28% in the treatment group, attenuating the contrast between the groups. Although this high rate of treatment in the usual care group makes it impossible to draw definitive conclusions from the ENRICHD data, it is clear that the results do not prove that depression and cardiac events are not causally related in patients with CHD.
Although the adjusted increases in risk of 2 to 2.5 associated with depression, currently being reported in epidemiologic studies of CHD, are impressive, it must be remembered that most CHD patients with depression do not die in the first few years following a cardiac event and that many patients without depression do not survive for long. Depression is not a very sensitive risk measure. This fact, combined with the high rate of antidepressant use in the ENRICHD usual care group, means that an extraordinarily efficacious treatment would have been needed in the experimental group to produce a difference in depression sufficient to markedly change the distal outcome of cardiac events. We do not yet have research-based evidence that such a powerful treatment or combination of treatments exists, even for depression patients without CHD. For example, the first report from the STAR*D study (57) , which recruited patients with depression from real world clinical settings, found that only 28% achieved remission (indicated by a 17-item HDRS score < 7) with up to 14 weeks of citalopram treatment. Even the most successful stepped collaborative care intervention evaluated to date in general practice patients (58) found only 40% of treated patients to be asymptomatic at 3 months, compared with 23% in the usual care group.
What Should Clinicians Do?
Psychiatrists and other physicians face many challenges when treating patients with CHD and depression. At minimum, the objective is to reduce levels of depressive symptoms and to improve quality of life without increasing cardiovascular risks. However, as summarized above, the evidence base is not very broad. Sertraline is safe for post-MI patients with mild-to-moderate ventricular dysfunction. There is evidence of superior efficacy to placebo in patients with recurrent depression, but the placebo response rate is high, and there is no evidence of efficacy for those with a first depression. Compared with usual care, 6 months of CBT has an effect size similar to sertraline, but it is difficult to estimate how much of this difference, as reported in the ENRICHD trial, was due to CBT itself.
The take-home message for clinicians is that sertraline is indicated for post-MI patients with a recurrent major depression. For those experiencing a first episode, waiting 1 or 2 months before prescribing a selective serotonin reuptake inhibitor is appropriate, since about 50% of these patients will remit spontaneously. In terms of psychotherapy, there are insufficient evidence-based data to guide clinicians in their choices. In this context, the most reasonable approach may be to use current practice guidelines for major depression that are based on research in non-CHD patients
Conclusions
In summary, although there has been some variability in outcomes, the recent literature provides additional support for an etiologic role of depression in the development of CHD. Results of recent prognostic studies have shown less consistency, primarily because of the continuing publication of small, underpowered studies that have not demonstrated a link between depression and CHD prognosis. Despite the wealth of scientific data supporting the epidemiologic association between depression and cardiac outcomes that has accumulated over the past 20 years, and despite the evidence that the relation may be causal, the lack of clinical trials remains a major limitation for making useful clinical recommendations. Although there is little concern regarding the cardiovascular safety of selective serotonin reuptake inhibitors or CBT for those for whom it is an available and acceptable treatment, more efficacy trials are needed, including trials evaluating combinations of antidepressant treatments.
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Résumé : Des données probantes récentes lient la maladie coronarienne et la dépression

Conclusions :
La documentation récente soutient encore le rôle tant étiologique que pronostique de la dépression dans la MC. Malgré ces données probantes, il y a eu peu d'essais cliniques du traitement de la dépression chez les patients de la MC, et aucun essai clinique de prévention de la dépression. Il faut d'autres essais.
